Research Ready™ Program Expands and Diversifies Clinical Trial Patient Populations
Austin, Texas, May 15, 2018 (BUSINESS WIRE) - Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, has launched a Research Ready™ program for physician practices interested in becoming a study site. Through the program, health care providers are able to offer clinical research studies as a care option to their patients. As a result, patient participation and retention rates increase, contributing to a more diverse population of patients and subsequently enabling clinical research organizations (CROs) and sponsors to get their studies up and running faster. The Research Ready™ program is part of Elligo’s Goes Direct™ approach, which provides a larger patient pool, more randomizations and better retention by making clinical research studies accessible to physicians and their patients. Through the program, physician practices are evaluated on a number of study-related components and are provided the technology, the infrastructure and a clinical coordinator to perform trials. “We know patient diversification is important for our trial sponsors and CROs,” said John Potthoff, Ph.D., CEO of Elligo. “We make it easier for more patients to participate in trials through their own trusted physician. And, not only are our sites benefiting from the infrastructure support, but our sponsors and CROs are getting quality study data from community practice researchers.” Every research site conducting research with Elligo has received the Research Ready™ designation. Currently, Elligo has more than 200 physician partners - with specialization in women’s health, gastroenterology, urology and pain management indications. About Elligo Health ResearchElligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct™ approach uses state-of-the-art elliGO DIRECT™ technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com. CONTACT: Lea Studer SCORR Marketing 402.366.1752
lea@scorrmarketing.com
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
